S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA

• M. L. Wang,
• W. Jurczak,
• M. Jerkeman,
• J. Trotman,
• P. L. Zinani,
• D. Belada,
• C. Boccomini,
• I. W. Flinn,
• P. Giri,
• A. Goy,
• P. A. Hamlin,
• O. Hermine,
• J.-Á. Hernández-Rivas,
• X. Hong,
• S. J. Kim,
• D. Lewis,
• Y. Mishima,
• M. Özcan,
• G. F. Perini,
• C. Pocock,
• Y. Song,
• S. E. Spurgeon,
• J. M. Storring,
• J. Walewski,
• J. Zhu,
• R. Qin,
• T. Henninger,
• S. Deshpande,
• A. Howes,
• S. Le Gouill,
• M. Dreyling

Affiliations

M. L. Wang

1 The University of Texas MD Anderson Cancer Center, Houston, United States of America

W. Jurczak

2 Maria Sklodowska-Curie National Research Institute of Oncology, Karkow, Poland

M. Jerkeman

3 Skane University Hospital and Lund University, Lund, Sweden

J. Trotman

4 Concord Repatriation General Hospital, University of Sydney, Sydney, Australia

P. L. Zinani

5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy

D. Belada

64 th Department of Internal Medicine - Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czechia

C. Boccomini

7 SC Ematologia, AOU Città della Salute e della Scienza di Torino - Presidio Molinette, Torino, Italy

I. W. Flinn

8 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, United States of America

P. Giri

9 Royal Adelaide Hospital, Adelaide, Australia

A. Goy

10 John Theurer Cancer Center, Hackensack

P. A. Hamlin

11 Memorial Sloan Kettering Cancer Center, New York, United States of America

O. Hermine

12 Department of Hematology, Hôpital Necker, Assistance Publique - Hôpitaux de Paris and Institut Imagine, Université de Paris, INSERM UMR1183, Paris, France

J.-Á. Hernández-Rivas

13 Department of Hematology, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain

X. Hong

14 Fudan University Shanghai Cancer Center, Shanghai, China

S. J. Kim

15 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

D. Lewis

16 University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom

Y. Mishima

17 Department of Hematology Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Toyo, Japan

M. Özcan

18 Ankara University School of Medicine, Ankara, Turkey

G. F. Perini

19 Hospital Israelita Albert Einstein, Sao Paulo, Brazil

C. Pocock

20 Kent and Canterbury Hospital, Canterbury, United Kingdom

Y. Song

21 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China

S. E. Spurgeon

22 Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, United States of America

J. M. Storring

23 The Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada

J. Walewski

24 Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland

J. Zhu

21 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China

R. Qin

25 Janssen Research & Development, Raritan, United States of America

T. Henninger

25 Janssen Research & Development, Raritan, United States of America

S. Deshpande

25 Janssen Research & Development, Raritan, United States of America

A. Howes

25 Janssen Research & Development, Raritan, United States of America

S. Le Gouill

26 Institut Curie comprehensive cancer center, Paris, France; Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Nantes Angers, INSERM, Université de Nantes, Nantes, France

M. Dreyling

27 Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany